EMGALITY 120 mg/mL
galcanezumab-gnlm · INJECTION, SOLUTION · Eli Lilly and Company
EMGALITY is a injection, solution containing galcanezumab-gnlm at 120 mg/mL, taken subcutaneous. Manufactured by Eli Lilly and Company.
Key Facts
- Brand Name
- EMGALITY
- Generic Name
- galcanezumab-gnlm
- NDC Code (Product)
0002-2377- Manufacturer
- Eli Lilly and Company
- Strength
- 120 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761063
- Marketing Start
- 09/27/2018
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is EMGALITY used for?
EMGALITY contains galcanezumab-gnlm. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is EMGALITY a controlled substance?
EMGALITY is not classified as a controlled substance by the DEA.
What is the generic name for EMGALITY?
The generic name for EMGALITY is galcanezumab-gnlm. There are no other listed brand versions of galcanezumab-gnlm.
What is the NDC code for EMGALITY 120 mg/mL?
The NDC (National Drug Code) for EMGALITY 120 mg/mL is 0002-2377, listed by Eli Lilly and Company.
Other EMGALITY Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)